Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model
Objectives: Chitosan is a green (natural, abundant, biodegradable, biocompatible) biopolymer that can be formulated to encapsulate a variety of therapeutic compounds. This study aimed to investigate chitosan nanoparticles (NPs) as a means of improving delivery of the clinically used anti-cancer agen...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
John Wiley & Sons Ltd.
2013
|
| Online Access: | http://hdl.handle.net/20.500.11937/49673 |
| _version_ | 1848758290760073216 |
|---|---|
| author | Tan, M. Friedhuber, A. Dass, Crispin |
| author_facet | Tan, M. Friedhuber, A. Dass, Crispin |
| author_sort | Tan, M. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Objectives: Chitosan is a green (natural, abundant, biodegradable, biocompatible) biopolymer that can be formulated to encapsulate a variety of therapeutic compounds. This study aimed to investigate chitosan nanoparticles (NPs) as a means of improving delivery of the clinically used anti-cancer agent doxorubicin (Dox) and the preclinical lead compound Dz13 oligonucleotide together. Methods: A novel chitosan NP system encapsulating Dox and Dz13 was designed, biophysically characterised and tested in a clinically relevant model of the metastasising bone tumour, osteosarcoma (OS). Key findings: By careful alteration of the concentration of the individual components, a final formulation of Dz13-Dox NPs (DDNPs) was achieved, with high (>91%) loading of both compounds, which consisted of individual 50-nm particles forming aggregates as large as 500 nm, with a large positive ζ-potential. The DDNPs could be stored at various temperatures for a week without loss in activity but were prone to degradation in serum. DDNPs successfully inhibited OS tumour growth more effectively than treatment with NPs of Dz13 and Dox-chitosan, as well as Dox administered intraperitoneally. Apart from inhibiting tumour growth, DDNPs protected the affected bone from substantial destruction by aggressive tumour growth and reduced the incidence of metastasis to the lungs without causing adverse effects in mice. Conclusion: This NP is a promising formulation that could be useful for clinical management of OS. |
| first_indexed | 2025-11-14T09:41:39Z |
| format | Journal Article |
| id | curtin-20.500.11937-49673 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:41:39Z |
| publishDate | 2013 |
| publisher | John Wiley & Sons Ltd. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-496732017-09-13T15:48:32Z Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model Tan, M. Friedhuber, A. Dass, Crispin Objectives: Chitosan is a green (natural, abundant, biodegradable, biocompatible) biopolymer that can be formulated to encapsulate a variety of therapeutic compounds. This study aimed to investigate chitosan nanoparticles (NPs) as a means of improving delivery of the clinically used anti-cancer agent doxorubicin (Dox) and the preclinical lead compound Dz13 oligonucleotide together. Methods: A novel chitosan NP system encapsulating Dox and Dz13 was designed, biophysically characterised and tested in a clinically relevant model of the metastasising bone tumour, osteosarcoma (OS). Key findings: By careful alteration of the concentration of the individual components, a final formulation of Dz13-Dox NPs (DDNPs) was achieved, with high (>91%) loading of both compounds, which consisted of individual 50-nm particles forming aggregates as large as 500 nm, with a large positive ζ-potential. The DDNPs could be stored at various temperatures for a week without loss in activity but were prone to degradation in serum. DDNPs successfully inhibited OS tumour growth more effectively than treatment with NPs of Dz13 and Dox-chitosan, as well as Dox administered intraperitoneally. Apart from inhibiting tumour growth, DDNPs protected the affected bone from substantial destruction by aggressive tumour growth and reduced the incidence of metastasis to the lungs without causing adverse effects in mice. Conclusion: This NP is a promising formulation that could be useful for clinical management of OS. 2013 Journal Article http://hdl.handle.net/20.500.11937/49673 10.1111/j.2042-7158.2012.01572.x John Wiley & Sons Ltd. restricted |
| spellingShingle | Tan, M. Friedhuber, A. Dass, Crispin Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model |
| title | Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model |
| title_full | Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model |
| title_fullStr | Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model |
| title_full_unstemmed | Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model |
| title_short | Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model |
| title_sort | co-nanoencapsulated doxorubicin and dz13 control osteosarcoma progression in a murine model |
| url | http://hdl.handle.net/20.500.11937/49673 |